The completed acquisition provides Albany Molecular Research (AMRI) with an immediate presence in Europe. In combination with AMRI’s facilities in the US and Asia, the acquisition enhances the company’s ability to offer a range of flexible services and cost models and provides a hub from which to establish additional relationships with European pharmaceutical and biotechnology companies.
AMRI is a drug discovery company that provides chemistry services to pharmaceutical and biotechnology companies and conducts its own proprietary R&D programs. ComGenex combines chemical synthesis and computational chemistry to create drug-like compounds.
“All of us at AMRI welcome ComGenex employees to our team. We look forward to achieving the synergies that can occur when two strong organizations combine resources,” said AMRI chairman, president and CEO Dr Thomas D’Ambra.